Al-Jafar HA
Research peptide BPC-157 BPC-157 is an experimental peptide with extensive animal research but very limited human evidence
Efficacy and safety of co-administered once-weekly cagrilintide 24 mg with once-weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
TIER 1 | 46mg total | $295 total cost , based on a titration from 0.5-1mg/day TIER 2 | 90mg total | $395 total cost , at 1.5mg/day TIER 3 | 120mg total | $495 total cost , at 2mg/day TIER 4 | 150mg total | $595 total cost , at 2.5mg/day Empower Pharmacy - Tirzepatide ODT (Orally Disintegrating Tablets) Up to 180 days BUD, all tiers include a 60 day supply
Tail spasticity Interestingly, the development of spasticity began earlier in the rats that underwent spinal cord injury and had been treated with BPC 157 than in the corresponding controls
They have undergone rigorous testing for safety and efficacy